Department of Cellular and Molecular Medicine University of California, San Diego, La Jolla, CA 92093-0712.
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093-0712.
Vaccine. 2012 Oct 12;30(46):6541-6550. doi: 10.1016/j.vaccine.2012.08.049. Epub 2012 Sep 1.
Herpes Simplex Virus Type 2 (HSV-2) infection can result in life-long recurrent genital disease, asymptomatic virus shedding, and transmission. No vaccine to date has shown significant protection clinically. Here, we used a mouse model of genital HSV-2 infection to test the efficacy of a vaccine consisting of whole, formalin-inactivated HSV-2 (FI-HSV2) formulated with monophosphoryl lipid A (MPL) and alum adjuvants. Vaccine components were administered alone or as a prime-boost immunization together with DNA vaccines encoding a truncated glycoprotein D2 (gD2t) and two conserved HSV-2 genes necessary for virus replication, UL5 (DNA helicase) and UL30 (DNA polymerase). Our results show: (1) compared with mock immunized controls, mice immunized with FI-HSV2 plus MPL/alum consistently showed protection against disease burden and total viral shedding while the mice immunized with gD2t protein with MPL/alum did not; (2) protection against genital disease and viral replication correlated with the type of boost in a prime-boost immunization with little advantage afforded by a DNA prime; (3) intramuscular (i.m.) immunization with FI-HSV2 in MPL/Alhydrogel adjuvant provided nearly complete protection against vaginal HSV-2 shedding after a lethal intravaginal (i.vag.) short-term challenge and long-term rechallenge; (4) single formulation immunization with DNA vaccines, FI-HSV2, and MPL in an aluminum phosphate (Adju-Phos) adjuvant did not increase protection relative to FI-HSV2/MPL/Adju-Phos alone; and (5) addition of MPL/alum to the FI-HSV2 was required for optimal protection against disease, viral replication, and latent virus load in the dorsal root ganglia (DRG). Most notably, an optimized vaccine formulation of FI-HSV2 MPL/Alhydrogel given i.m. completely protected against detectable vaginal HSV-2 shedding in the majority of animals and HSV-2 latent DNA in the DRG of all animals.
单纯疱疹病毒 2 型(HSV-2)感染可导致终身复发性生殖器疾病、无症状病毒脱落和传播。迄今为止,尚无疫苗在临床上显示出显著的保护作用。在这里,我们使用生殖器单纯疱疹病毒 2 型(HSV-2)感染的小鼠模型来测试由全细胞、福尔马林灭活单纯疱疹病毒 2 型(FI-HSV2)与单磷酰脂质 A(MPL)和铝佐剂组成的疫苗的功效。疫苗成分单独使用或作为与编码截短糖蛋白 D2(gD2t)和两种用于病毒复制的单纯疱疹 2 型保守基因 UL5(DNA 解旋酶)和 UL30(DNA 聚合酶)的 DNA 疫苗的初免-加强免疫一起使用。我们的结果表明:(1)与模拟免疫对照相比,用 FI-HSV2 加 MPL/ 铝佐剂免疫的小鼠始终表现出对疾病负担和总病毒脱落的保护作用,而用 MPL/ 铝佐剂免疫 gD2t 蛋白的小鼠则没有;(2)对生殖器疾病和病毒复制的保护作用与初免-加强免疫中的增强类型相关,DNA 初免几乎没有优势;(3)在 MPL/Alhydrogel 佐剂中肌肉内(i.m.)免疫 FI-HSV2 在致命的阴道内(i.vag.)短期挑战和长期再挑战后几乎完全防止阴道单纯疱疹 2 型脱落;(4)用 DNA 疫苗、FI-HSV2 和铝磷酸(Adju-Phos)佐剂的单一配方免疫不会增加相对于单独使用 FI-HSV2/MPL/Adju-Phos 的保护作用;(5)FI-HSV2 中添加 MPL/ 铝佐剂是预防疾病、病毒复制和背根神经节(DRG)潜伏病毒载量的最佳保护所必需的。值得注意的是,肌肉内给予优化的 FI-HSV2 MPL/Alhydrogel 疫苗配方完全保护大多数动物的阴道单纯疱疹 2 型脱落和所有动物的 DRG 中单纯疱疹 2 型潜伏 DNA 免受检测。